BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 24731156)

  • 1. Low iodine diet for one week is sufficient for adequate preparation of high dose radioactive iodine ablation therapy of differentiated thyroid cancer patients in iodine-rich areas.
    Lee M; Lee YK; Jeon TJ; Chang HS; Kim BW; Lee YS; Park CS; Ryu YH
    Thyroid; 2014 Aug; 24(8):1289-96. PubMed ID: 24731156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patients.
    Tala Jury HP; Castagna MG; Fioravanti C; Cipri C; Brianzoni E; Pacini F
    J Clin Endocrinol Metab; 2010 Jan; 95(1):230-7. PubMed ID: 19858316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer.
    Sohn SY; Choi JY; Jang HW; Kim HJ; Jin SM; Kim SW; Suh S; Hur KY; Kim JH; Chung JH; Kim SW
    Thyroid; 2013 Jun; 23(6):741-7. PubMed ID: 23205883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of iodinated contrast agent administered during preoperative computed tomography scan on body iodine pool in patients with differentiated thyroid cancer preparing for radioactive iodine treatment.
    Sohn SY; Choi JH; Kim NK; Joung JY; Cho YY; Park SM; Kim TH; Jin SM; Bae JC; Lee SY; Chung JH; Kim SW
    Thyroid; 2014 May; 24(5):872-7. PubMed ID: 24295076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daily urine iodine excretion while consuming a low-iodine diet in preparation for radioactive iodine therapy in a high iodine intake area.
    Kim HK; Lee SY; Lee JI; Jang HW; Kim SK; Chung HS; Tan AH; Hur KY; Kim JH; Chung JH; Kim SW
    Clin Endocrinol (Oxf); 2011 Dec; 75(6):851-6. PubMed ID: 21707689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer.
    Caglar M; Bozkurt FM; Akca CK; Vargol SE; Bayraktar M; Ugur O; Karaağaoğlu E
    Nucl Med Commun; 2012 Mar; 33(3):268-74. PubMed ID: 22205241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma.
    Pluijmen MJ; Eustatia-Rutten C; Goslings BM; Stokkel MP; Arias AM; Diamant M; Romijn JA; Smit JW
    Clin Endocrinol (Oxf); 2003 Apr; 58(4):428-35. PubMed ID: 12641625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low iodine diet in differentiated thyroid cancer: a review.
    Li JH; He ZH; Bansal V; Hennessey JV
    Clin Endocrinol (Oxf); 2016 Jan; 84(1):3-12. PubMed ID: 26118628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
    Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
    Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of body iodine pool assessment methods before radioiodine therapy.
    Genc M; Yildirim A; Yildirim N
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2024; 43(2):107-112. PubMed ID: 38331249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-Iodine Diet of 4 Days Is Sufficient Preparation for 131I Therapy in Differentiated Thyroid Cancer Patients.
    Dekker BL; Links MH; Muller Kobold AC; Swart-Busscher LG; Kars M; Bons JAP; Brouwers AH; Links TP; van der Horst-Schrivers ANA
    J Clin Endocrinol Metab; 2022 Jan; 107(2):e604-e611. PubMed ID: 34534327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal.
    Elisei R; Schlumberger M; Driedger A; Reiners C; Kloos RT; Sherman SI; Haugen B; Corone C; Molinaro E; Grasso L; Leboulleux S; Rachinsky I; Luster M; Lassmann M; Busaidy NL; Wahl RL; Pacini F; Cho SY; Magner J; Pinchera A; Ladenson PW
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4171-9. PubMed ID: 19850694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Outcome of Remnant Thyroid Ablation with Low Dose Radioiodine in Korean Patients with Low to Intermediate-risk Thyroid Cancer.
    Ha S; Oh SW; Kim YK; Koo do H; Jung YH; Yi KH; Chung JK
    J Korean Med Sci; 2015 Jul; 30(7):876-81. PubMed ID: 26130949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
    Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postoperative-stimulated serum thyroglobulin measured at the time of 131I ablation is useful for the prediction of disease status in patients with differentiated thyroid carcinoma.
    Lee JI; Chung YJ; Cho BY; Chong S; Seok JW; Park SJ
    Surgery; 2013 Jun; 153(6):828-35. PubMed ID: 23489940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive factors for the outcomes of initial I-131 low-dose ablation therapy to Japanese patients with differentiated thyroid cancer.
    Ito S; Iwano S; Kato K; Naganawa S
    Ann Nucl Med; 2018 Jul; 32(6):418-424. PubMed ID: 29766463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer.
    Padovani RP; Robenshtok E; Brokhin M; Tuttle RM
    Thyroid; 2012 Aug; 22(8):778-83. PubMed ID: 22780333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum thyroglobulin level after radioiodine therapy (Day 3) to predict successful ablation of thyroid remnant in postoperative thyroid cancer.
    Kim YI; Im HJ; Paeng JC; Cheon GJ; Kang KW; Lee DS; Joon Park D; Park YJ; Chung JK
    Ann Nucl Med; 2015 Feb; 29(2):184-9. PubMed ID: 25404419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
    Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is empirical radioactive iodine therapy still a valid approach to patients with thyroid cancer and elevated thyroglobulin?
    Rosario PW; Mourão GF; dos Santos JB; Calsolari MR
    Thyroid; 2014 Mar; 24(3):533-6. PubMed ID: 24067080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.